KaminskiCYGalindoRJNavarreteJE, et al. Assessment of glycemic control by continuous glucose monitoring, hemoglobin A1c, fructosamine, and glycated albumin in patients with end-stage kidney disease and burnt-out diabetes. Diabetes Care. 2024;47(2):267-271. doi:10.2337/dc23-1276.
2.
WangRColmanPGKyiMRussellNFourlanosS. Longitudinal prevalence of inpatient diabetes mellitus in an Australian hospital across five decades: 1972-2019. Intern Med J. 2021;51(5):814-815. doi:10.1111/imj.15322.
3.
AvariPTangWJugneeN, et al. The accuracy of continuous glucose sensors in people with diabetes undergoing hemodialysis (ALPHA study). Diabetes Technol Ther. 2023;25(7):447-456. doi:10.1089/dia.2023.0013.
4.
ÓlafsdóttirAFAndelinMSaeedA, et al. Performance of Dexcom G5 and FreeStyle Libre sensors tested simultaneously in people with type 1 or 2 diabetes and advanced chronic kidney disease. World J Clin Cases. 2022;10(22):7794-7807. doi:10.12998/wjcc.v10.i22.7794.
5.
ToyodaMMurataTSaitoN, et al. Assessment of the accuracy of an intermittent-scanning continuous glucose monitoring device in patients with type 2 diabetes mellitus undergoing hemodialysis (AIDT2H) study. Ther Apher Dial. 2021;25(5):586-594. doi:10.1111/1744-9987.13618.
6.
LuJCLeePIerinoFMacIsaacRJEkinciEO’NealD. Challenges of glycemic control in people with diabetes and advanced kidney disease and the potential of automated insulin delivery. J Diabetes Sci Technol. 2024;18(6):1500-1508. doi:10.1177/19322968231174040.
